Clinical Trials Logo
  1. Home
  2. Differentiated Thyroid Cancer
  3. NCT03191643
  4. Details
NCT03191643 Clinical Trial

PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer

Differentiated Thyroid Cancer Clinical Trial

Official title:
18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03191643
Other study ID # Thyroid-COBRA
Secondary ID
Status Completed
Phase N/A
First received June 15, 2017
Last updated June 16, 2017
Start date October 1, 2011
Est. completion date January 31, 2016

Study information
Verified date June 2017
Source Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Description of the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

Description:

The role of post-operative external beam radiotherapy (EBRT) in differentiated thyroid cancer is still discussed considering the low clinical aggressiveness and the availability of ablative 131Iodine therapy. However, there is a subgroup of tumors which lose the ability to capture Iodine over time. This study wants to describe the role of a post-operative external beam radiotherapy in patients with differentiated thyroid cancer.

Recruitment information / eligibility
Status Completed
Enrollment 16
Est. completion date January 31, 2016
Est. primary completion date January 31, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- detectable thyroglobulin (Tg),

- negative post-metabolic radiotherapy whole body scintigraphy,

- no surgical indications.

Exclusion Criteria:

- prior radiotherapy in the head and neck area

- pregnancy

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi

Outcome
Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) Progression-free survival (PFS) after radiotherapy is evaluated with CT-scan and 18F FDG PET-scan. Also laboratory tests are performed (HTG serum level evaluation in case of biochemical recurrence). 6 months
Secondary toxicities Acute and late toxicities after radiotherapy are assessed with CTCAE v. 4.03 and EORTC-RTOG scales, respectively. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer Phase 2
Completed NCT01876784 - Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer Phase 3
Completed NCT04971473 - Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal Phase 3
Recruiting NCT04964284 - Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer Phase 3
Recruiting NCT05078853 - Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
Active, not recruiting NCT03690388 - A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy Phase 3
Recruiting NCT02638077 - Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China N/A
Recruiting NCT01700699 - Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT04563780 - The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
Completed NCT02278198 - Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123 Phase 1
Active, not recruiting NCT04447183 - The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. Phase 2
Active, not recruiting NCT01263951 - Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone Phase 2
Active, not recruiting NCT04940052 - Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer Phase 3
Recruiting NCT04880798 - Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer N/A
Recruiting NCT05789667 - Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Recruiting NCT05660954 - Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Phase 2
Completed NCT00295763 - A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Phase 3
Recruiting NCT04321954 - Lenvatinib in Locally Advanced Invasive Thyroid Cancer Phase 2